H Koga

Summary

Affiliation: Kurume University School of Medicine
Country: Japan

Publications

  1. request reprint
    Koga H, Sakisaka S, Harada M, Takagi T, Hanada S, Taniguchi E, et al. Involvement of p21(WAF1/Cip1), p27(Kip1), and p18(INK4c) in troglitazone-induced cell-cycle arrest in human hepatoma cell lines. Hepatology. 2001;33:1087-97 pubmed
    ..These findings suggested that p21, p27, and p18 might be involved in troglitazone-induced cell-cycle arrest in human hepatoma cells. ..
  2. Koga H, Selvendiran K, Sivakumar R, Yoshida T, Torimura T, Ueno T, et al. PPAR? potentiates anticancer effects of gemcitabine on human pancreatic cancer cells. Int J Oncol. 2012;40:679-85 pubmed publisher
    ..Since Pio is widely used in the treatment of diabetes mellitus, it may become a feasible partner of Gem-based chemotherapy, fine-tuning the strength of the therapy in a dosage-dependent fashion. ..
  3. Ikezono Y, Koga H, Akiba J, Abe M, Yoshida T, Wada F, et al. Pancreatic Neuroendocrine Tumors and EMT Behavior Are Driven by the CSC Marker DCLK1. Mol Cancer Res. 2017;15:744-752 pubmed publisher
    ..i>Mol Cancer Res; 15(6); 744-52. ©2017 AACR. ..

Locale

Detail Information

Publications3

  1. request reprint
    Koga H, Sakisaka S, Harada M, Takagi T, Hanada S, Taniguchi E, et al. Involvement of p21(WAF1/Cip1), p27(Kip1), and p18(INK4c) in troglitazone-induced cell-cycle arrest in human hepatoma cell lines. Hepatology. 2001;33:1087-97 pubmed
    ..These findings suggested that p21, p27, and p18 might be involved in troglitazone-induced cell-cycle arrest in human hepatoma cells. ..
  2. Koga H, Selvendiran K, Sivakumar R, Yoshida T, Torimura T, Ueno T, et al. PPAR? potentiates anticancer effects of gemcitabine on human pancreatic cancer cells. Int J Oncol. 2012;40:679-85 pubmed publisher
    ..Since Pio is widely used in the treatment of diabetes mellitus, it may become a feasible partner of Gem-based chemotherapy, fine-tuning the strength of the therapy in a dosage-dependent fashion. ..
  3. Ikezono Y, Koga H, Akiba J, Abe M, Yoshida T, Wada F, et al. Pancreatic Neuroendocrine Tumors and EMT Behavior Are Driven by the CSC Marker DCLK1. Mol Cancer Res. 2017;15:744-752 pubmed publisher
    ..i>Mol Cancer Res; 15(6); 744-52. ©2017 AACR. ..